Company Profiles

driven by the PitchBook Platform

Annexon Bioscience

Description

Developer of novel disease-modifying drugs to treat neurodegenerative disorders. The company is developing a pipeline of classical complement pathway inhibitors focused on therapies for complement-mediated loss of nerve connections in the brain, as occurs in Alzheimer's disease and Huntington's disease, as well as in retinal cells, as seen in glaucoma.

2011

Founded

PRIVATE

Status

Series B

Latest Deal Type

$44M

Latest Deal Amount

$79M

Total Amount Raised

5

Investors

Description

Developer of novel disease-modifying drugs to treat neurodegenerative disorders. The company is developing a pipeline of classical complement pathway inhibitors focused on therapies for complement-mediated loss of nerve connections in the brain, as occurs in Alzheimer's disease and Huntington's disease, as well as in retinal cells, as seen in glaucoma.

Website:

www.annexonbio.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Biotechnology

Primary Office

280 Utah Avenue Suite 110 South San Francisco, CA 94080United States +1 (650) 822-5500
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Annexon Bioscience's full profile, request a free trial.

    Annexon Bioscience Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Annexon Bioscience Cap Table

    Stock# of Shares
    Authorized
    Par ValueDividend Rate (%)Original
    Issue Price
    LiquidationLiquidation
    Pref. Multiple
    Conversion
    Price
    % Owned

    Annexon Bioscience Investors (5)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    Clarus VenturesVenture CapitalMinority000 0000000 0000
    Correlation VenturesVenture CapitalMinority000 0000000 0000
    New Enterprise AssociatesVenture CapitalMinority000 0000000 0000
    Novartis Venture FundsCorporate Venture CapitalMinority000 0000000 0000
    Satter FoundationFamily OfficeMinority000 0000000 0000
    Clarus Ventures Venture Capital
    Correlation Ventures Venture Capital
    New Enterprise Associates Venture Capital
    Novartis Venture Funds Corporate Venture Capital
    Satter Foundation Family Office

    Annexon Bioscience Executive Team (5)

    NameTitleBoard
    Seat
    Contact
    Info
    Douglas Love JDChief Executive Officer, President & Board Member
    Ted Yednock Ph.DChief Scientific Officer
    Ben Barres Ph.DCo-Founder
    Susan KramerVice President, Product Development
    Mario Saltarelli Ph.DChief Medical Officer
    Douglas Love JD Chief Executive Officer, President & Board Member
    Ted Yednock Ph.D Chief Scientific Officer
    Ben Barres Ph.D Co-Founder
    Susan Kramer Vice President, Product Development
    Mario Saltarelli Ph.D Chief Medical Officer

    Annexon Bioscience Board Members (9)

    NameRepresentingRoleSinceContact
    Info
    Arnon Rosenthal Ph.DSelfCo-Founder & Chairman000 0000
    Campbell Murray MDNovartis Venture FundsManaging Director000 0000
    Douglas Love JDAnnexon BioscienceChief Executive Officer, President & Board Member000 0000
    Emmett Cunningham Jr.Clarus VenturesPartner000 0000
    Frank Torti MDNew Enterprise AssociatesPartner000 0000
    Arnon Rosenthal Ph.D Co-Founder & Chairman Self
    Campbell Murray MD Managing Director Novartis Venture Funds
    Douglas Love JD Chief Executive Officer, President & Board Member Annexon Bioscience
    Emmett Cunningham Jr. Partner Clarus Ventures
    Frank Torti MD Partner New Enterprise Associates
    Request full access to PitchBook